Webinar Today

7,111 upcoming
MedicalZoom

Topics › Medical & Clinical

'RLT for Solid Tumors: Why Now? A CEA-PRIT 2.0 Perspective' EACR and Roche webinar

Free

Length
1 hr
Platform
Zoom
Topic
Medical & Clinical

Get notified when the recording is available

We’ll email you once, when this recording is ready, with an unsubscribe link. See our privacy policy.

About this webinar

Talk abstract:

Radioligand therapy (RLT) has transformed systemic cancer treatment by delivering targeted radiation to tumors while limiting the exposure to healthy tissue. However, expanding into broader solid tumor indications requires optimising every design lever—from target selection to delivery kinetics and payload selection—to maximize the therapeutic index.

This EACR and Roche webinar explores the translation of pretargeted alpha therapy for carcinoembryonic antigen (CEA)–expressing solid tumors, focusing on CEA-PRIT 2.0, an optimised two-step pretargeting platform utilising lead-212 (212Pb).

Across three complementary perspectives, the session covers:

1. Clinical Rationale & Target Criteria: Why historical CEA radioimmunotherapy struggled with therapeutic index, and how pretargeted alpha emitters address these limitations.

2. Preclinical Discovery & Mechanism of Action: How SPLIT bispecific antibodies enable targeted 212Pb-DOTAM capture, showing strong tumor retention and favorable biodistribution.

3. Clinical Translation in Refractory MSS mCRC: Addressing high unmet need in MSS mCRC via the CEA-PRIT 2.0 first-in-human trial, covering imaging, dosimetry, escalation, and combination strategies.

Attendees will gain insights into how advanced radionuclide delivery platforms can overcome historical barriers and unlock the full potential of alpha-emitting radioligands in solid oncology.

Format:

A 60-minute webinar with time at the end for participants to ask questions.

More Medical webinars 828

All Medical →

All Medical (828)